Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Authors

Bruno C. Medeiros, Stanford University
Kelly McCaul, Avera Cancer Institute, Sioux Falls
Suman Kambhampati, Kansas University Medical Center
Daniel A. Pollyea, University of Colorado, Denver
Rajat Kumar, CancerCare Manitoba
Lewis R. Silverman, Mount Sinai Hospital, New York
Andrea Kew, Queen Elizabeth II Health Sciences Center, Halifax
Lalit Saini, University of Alberta
C. L. Beach, Celgene Corporation
Ravi Vij, Washington University School of Medicine in St. Louis
Xiwei Wang, Celgene Corporation
Jim Zhong, Celgene Corporation
Robert Peter Gale, Imperial College London

Journal

Haematologica

Publication Date

2018

Volume

103

Issue

1

First Page

101

Last Page

106

Document Type

Open Access Publication

DOI

10.3324/haematol.2017.172353

Rights and Permissions

Bruno C. Medeiros, et al. (2018) Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. Haematologica 103(1):101-106. doi: 10.3324/haematol.2017.172353. Obtained from the Haematologica Journal website http://www.haematologica.org

Recommended Citation

Medeiros, Bruno C.; McCaul, Kelly; Kambhampati, Suman; Pollyea, Daniel A.; Kumar, Rajat; Silverman, Lewis R.; Kew, Andrea; Saini, Lalit; Beach, C. L.; Vij, Ravi; Wang, Xiwei; Zhong, Jim; and Gale, Robert Peter, "Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia." Haematologica. 103, 1. 101 - 106. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8067